CSS
TPTX

Cubist Systematic Strategies’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Cubist Systematic Strategies’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-13,338
Closed -$1M – 5036
2022
Q2 		$1M Sell
13,338
-69,515
-84% -$3.09M 0.01% 2483
2022
Q1 		$2.23M Buy
82,853
+61,345
+285% +$2.06M 0.02% 1396
2021
Q4 		$1.03M Buy
21,508
+1,858
+9% +$83.1K 0.01% 1894
2021
Q3 		$1.3M Sell
19,650
-4,727
-19% -$337K 0.02% 1320
2021
Q2 		$1.9M Sell
24,377
-12,740
-34% -$941K 0.02% 1108
2021
Q1 		$3.51M Buy
37,117
+18,200
+96% +$2.16M 0.04% 647
2020
Q4 		$2.31M Buy
18,917
+4,092
+28% +$448K 0.03% 858
2020
Q3 		$1.29M Buy
+14,825
New +$1.03M 0.02% 1180
2020
Q2 		– Sell
-6,578
Closed -$294K – 2581
2020
Q1 		$294K Sell
6,578
-16,110
-71% -$856K 0.01% 1535
2019
Q4 		$1.41M Buy
+22,688
New +$1.08M 0.03% 950
2019
Q3 		– Sell
-2,215
Closed -$90K – 2589
2019
Q2 		$90K Buy
+2,215
New +$79K ﹤0.01% 2250

Cubist Systematic Strategies's TPTX Position: Q3 2022 in Review

Cubist Systematic Strategies sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 13,338 shares — an estimated $1M sold.

Cubist Systematic Strategies first reported a position in TPTX in Q2 2019 and held it in 11 quarters. The position peaked at $3.51M in Q1 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Cubist Systematic Strategies reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Cubist Systematic Strategies sold 13,338 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $1M.
  • Cubist Systematic Strategies first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 11 quarters.
  • Cubist Systematic Strategies's Turning Point Therapeutics, Inc. Common Stock position peaked at $3.51M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Cubist Systematic Strategies's 13F filing for Q3 2022, filed 14 Nov 2022.